Creative Peptides Added New GLP-1 Peptides for Diabetes Research

On January 11, 2018, the leading peptide expert Creative Peptides announced to add new GLP-1 peptides targeting for diabetes research.

On January 11, 2018, the leading peptide expert Creative Peptides announced to add new GLP-1 peptides targeting for diabetes research.

Diabetes is a chronic disease that affects a large number of population. According to the latest report from World Health Organization, 422 million people have diabetes worldwide. This number was 108 million in 1980. In spite of concerted efforts from all sides, the status quo still has no signs of relief or under control.

The cause of diabetes is closely connected with insulin, a hormone that regulates blood sugar. When the pancreas does not produce enough insulin or when the body cannot effectively utilize the insulin it produces, diabetes occurs. Generally there are two types: Type 1 diabetes and Type 2 Diabetes. About ninety percent of diabetes cases belong to the latter type, which was characterized by insulin resistance and the body’s inability to secrete enough insulin.

“GLP-1 peptide is secreted from intestinal enteroendocrine L cells and can control systemic blood glucose homeostasis in humans after a meal,” said Dr. Robert Martinez, the leading scientist at Creative Peptides. Based on a variety of complementary working mechanisms of GLP-1, scientists have discovered new therapies as novel treatment options for type 2 diabetes. “Unlike other diabetes drugs, the insulinotropic effect of GLP-1 is self-limiting, as it falls once the plasma glucose level is lowered to normal range, reducing the risk of hypoglycemia,” added Dr. Robert Martinez.

Besides, through several other mechanisms, GLP-1 peptides also can: promote insulin gene transcription, stimulate pancreatic β-cell proliferation and neogenesis, inhibit β-cell apoptosis, and blockglucagon release. It also proved to be effective in lowering body weight.

Creative Peptides now adds quite a number of GLP-1 peptides to its collection, for example, lixisenatide, liraglutide and exenatide. All could be applied in diabetes research. Liraglutide even has gained approval from FDA and was marketed under the brand name Victoza as an injectable drug to treat type 2 diabetes.

About Creative Peptides

With over a dozen of years’ experience in peptide manufacturing and synthesis, Creative Peptides has made commendable achievements in custom peptide synthesis, GMP manufacturing, API peptides, cosmetic peptides, catalog peptides, etc. With the advantage of excellent scientific teams consisting of experts in multiple fields like peptide technology, antibodies as well as synthetic chemistry, Creative Peptides now focus more on satisfying different needs of customers by providing a series of services, including peptide drug bioconjugations, custom peptide synthesis, cell penetrating peptides synthesis services, etc.

MORE ON THIS TOPIC